Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75832
UPID:
PSD10_HUMAN
Alternative names:
26S proteasome regulatory subunit p28; Gankyrin; p28(GANK)
Alternative UPACC:
O75832; Q5U0B2; Q8IZK9
Background:
The 26S proteasome non-ATPase regulatory subunit 10, also known as Gankyrin or p28(GANK), plays a crucial role in cellular processes. It acts as a chaperone during the assembly of the 26S proteasome, particularly the PA700/19S regulatory complex, influencing proteasome structure and function. Beyond its proteasomal duties, Gankyrin regulates EGF-induced AKT activation, RAS-induced tumorigenesis, and has a pivotal role in the negative regulation of tumor suppressors RB1 and p53/TP53.
Therapeutic significance:
Understanding the role of 26S proteasome non-ATPase regulatory subunit 10 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways and tumor suppressor regulation highlights its potential as a target in cancer therapy.